Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Sulfatinib in Healthy Subjects
NCT02320409Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of surufatinib in neuroendocrine tumors (NETs) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Pharmacokinetic parameters. Started Dec 2014; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02320409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320409.